Role of anti-vimentin antibodies in renal transplantation

The role of non-HLA antibodies in rejection is not clear. We investigate whether antibodies to vimentin are made after renal transplantation and if production is associated with interstitial fibrosis and tubular atrophy (IFTA). In this retrospective study, sera from 70 recipients of renal allografts...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Transplantation Ročník 98; číslo 1; s. 72
Hlavní autoři: Besarani, Dler, Cerundolo, Lucia, Smith, John D, Procter, Jeanette, Barnardo, Martin C N, Roberts, Ian S D, Friend, Peter J, Rose, Marlene L, Fuggle, Susan V
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 15.07.2014
Témata:
Adult
Atrophy
Biopsy
Female
Fibrosis
HLA Antigens - immunology
Humans
Immunoglobulin G - blood
Immunoglobulin M - blood
Isoantibodies - blood
Kidney Diseases - blood
Kidney Diseases - immunology
Kidney Diseases - pathology
Kidney Transplantation - adverse effects
Male
Middle Aged
Retrospective Studies
Risk Factors
Time Factors
Treatment Outcome
Vimentin - immunology
ISSN:1534-6080, 1534-6080
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract The role of non-HLA antibodies in rejection is not clear. We investigate whether antibodies to vimentin are made after renal transplantation and if production is associated with interstitial fibrosis and tubular atrophy (IFTA). In this retrospective study, sera from 70 recipients of renal allografts (40 controls, 30 IFTA) were studied. The biopsy diagnosis of interstitial fibrosis and tubular atrophy (IFTA) was based on random, cause-indicating biopsies. Sera were collected pretransplant and at 3 monthly intervals up to 5 years posttransplant or diagnosis of IFTA and assayed by ELISA for IgM and IgG anti-vimentin antibodies (AVA) and HLA antibodies. Mean titers of IgM AVA were higher at every year after transplantation compared with pretransplant for both IFTA and controls groups (P<0.001). There was no difference in the mean level of IgM AVA achieved by IFTA and control groups. The mean pretransplant levels of IgG AVA in the IFTA and control group were 18.2±11.7 and 11.0±8.1, respectively (P=0.001). There was a significant increase between the pretransplant mean levels of IgG AVA and the levels at years 1 to 4 in the IFTA group (years 1-3, P<0.0001, year 4 P=0.003) but not in the controls. There was no significant difference between the numbers of IFTA or control patients achieving a positive value (mean+2SD of pretransplant antibody titers) of IgM AVA (50% versus 37.5%, respectively) or IgG AVA (26.6% versus 12.5%, respectively). There was no association between production of HLA and AVA antibodies. Posttransplant production of IgM AVA is not associated with IFTA. The production of IgG AVA by a minority of IFTA patients suggests that in some individuals, IgG AVA may be involved in the pathology of IFTA.
AbstractList The role of non-HLA antibodies in rejection is not clear. We investigate whether antibodies to vimentin are made after renal transplantation and if production is associated with interstitial fibrosis and tubular atrophy (IFTA).BACKGROUNDThe role of non-HLA antibodies in rejection is not clear. We investigate whether antibodies to vimentin are made after renal transplantation and if production is associated with interstitial fibrosis and tubular atrophy (IFTA).In this retrospective study, sera from 70 recipients of renal allografts (40 controls, 30 IFTA) were studied. The biopsy diagnosis of interstitial fibrosis and tubular atrophy (IFTA) was based on random, cause-indicating biopsies. Sera were collected pretransplant and at 3 monthly intervals up to 5 years posttransplant or diagnosis of IFTA and assayed by ELISA for IgM and IgG anti-vimentin antibodies (AVA) and HLA antibodies.METHODSIn this retrospective study, sera from 70 recipients of renal allografts (40 controls, 30 IFTA) were studied. The biopsy diagnosis of interstitial fibrosis and tubular atrophy (IFTA) was based on random, cause-indicating biopsies. Sera were collected pretransplant and at 3 monthly intervals up to 5 years posttransplant or diagnosis of IFTA and assayed by ELISA for IgM and IgG anti-vimentin antibodies (AVA) and HLA antibodies.Mean titers of IgM AVA were higher at every year after transplantation compared with pretransplant for both IFTA and controls groups (P<0.001). There was no difference in the mean level of IgM AVA achieved by IFTA and control groups. The mean pretransplant levels of IgG AVA in the IFTA and control group were 18.2±11.7 and 11.0±8.1, respectively (P=0.001). There was a significant increase between the pretransplant mean levels of IgG AVA and the levels at years 1 to 4 in the IFTA group (years 1-3, P<0.0001, year 4 P=0.003) but not in the controls. There was no significant difference between the numbers of IFTA or control patients achieving a positive value (mean+2SD of pretransplant antibody titers) of IgM AVA (50% versus 37.5%, respectively) or IgG AVA (26.6% versus 12.5%, respectively). There was no association between production of HLA and AVA antibodies.RESULTSMean titers of IgM AVA were higher at every year after transplantation compared with pretransplant for both IFTA and controls groups (P<0.001). There was no difference in the mean level of IgM AVA achieved by IFTA and control groups. The mean pretransplant levels of IgG AVA in the IFTA and control group were 18.2±11.7 and 11.0±8.1, respectively (P=0.001). There was a significant increase between the pretransplant mean levels of IgG AVA and the levels at years 1 to 4 in the IFTA group (years 1-3, P<0.0001, year 4 P=0.003) but not in the controls. There was no significant difference between the numbers of IFTA or control patients achieving a positive value (mean+2SD of pretransplant antibody titers) of IgM AVA (50% versus 37.5%, respectively) or IgG AVA (26.6% versus 12.5%, respectively). There was no association between production of HLA and AVA antibodies.Posttransplant production of IgM AVA is not associated with IFTA. The production of IgG AVA by a minority of IFTA patients suggests that in some individuals, IgG AVA may be involved in the pathology of IFTA.CONCLUSIONPosttransplant production of IgM AVA is not associated with IFTA. The production of IgG AVA by a minority of IFTA patients suggests that in some individuals, IgG AVA may be involved in the pathology of IFTA.
The role of non-HLA antibodies in rejection is not clear. We investigate whether antibodies to vimentin are made after renal transplantation and if production is associated with interstitial fibrosis and tubular atrophy (IFTA). In this retrospective study, sera from 70 recipients of renal allografts (40 controls, 30 IFTA) were studied. The biopsy diagnosis of interstitial fibrosis and tubular atrophy (IFTA) was based on random, cause-indicating biopsies. Sera were collected pretransplant and at 3 monthly intervals up to 5 years posttransplant or diagnosis of IFTA and assayed by ELISA for IgM and IgG anti-vimentin antibodies (AVA) and HLA antibodies. Mean titers of IgM AVA were higher at every year after transplantation compared with pretransplant for both IFTA and controls groups (P<0.001). There was no difference in the mean level of IgM AVA achieved by IFTA and control groups. The mean pretransplant levels of IgG AVA in the IFTA and control group were 18.2±11.7 and 11.0±8.1, respectively (P=0.001). There was a significant increase between the pretransplant mean levels of IgG AVA and the levels at years 1 to 4 in the IFTA group (years 1-3, P<0.0001, year 4 P=0.003) but not in the controls. There was no significant difference between the numbers of IFTA or control patients achieving a positive value (mean+2SD of pretransplant antibody titers) of IgM AVA (50% versus 37.5%, respectively) or IgG AVA (26.6% versus 12.5%, respectively). There was no association between production of HLA and AVA antibodies. Posttransplant production of IgM AVA is not associated with IFTA. The production of IgG AVA by a minority of IFTA patients suggests that in some individuals, IgG AVA may be involved in the pathology of IFTA.
Author Fuggle, Susan V
Friend, Peter J
Barnardo, Martin C N
Smith, John D
Roberts, Ian S D
Rose, Marlene L
Besarani, Dler
Procter, Jeanette
Cerundolo, Lucia
Author_xml – sequence: 1
  givenname: Dler
  surname: Besarani
  fullname: Besarani, Dler
  organization: 1 Transplant Immunology and Immunogenetics, Oxford Transplant Centre, Oxford University Hospitals NHS Trust, Oxford, UK. 2 Nuffield Department of Surgical Sciences, University of Oxford, Oxford University Hospitals NHS Trust, Oxford, UK. 3 Transplant Immunology, Harefield Hospital, Imperial College, Harefield, UK. 4 Department of Cellular Pathology, Oxford University Hospitals NHS Trust, Oxford, UK. 5 Address correspondence to: Dler Besarani, MRCS, MSc, MD, Oxford Transplant Centre, Churchill Hospital, Oxford, OX3 7LE
– sequence: 2
  givenname: Lucia
  surname: Cerundolo
  fullname: Cerundolo, Lucia
– sequence: 3
  givenname: John D
  surname: Smith
  fullname: Smith, John D
– sequence: 4
  givenname: Jeanette
  surname: Procter
  fullname: Procter, Jeanette
– sequence: 5
  givenname: Martin C N
  surname: Barnardo
  fullname: Barnardo, Martin C N
– sequence: 6
  givenname: Ian S D
  surname: Roberts
  fullname: Roberts, Ian S D
– sequence: 7
  givenname: Peter J
  surname: Friend
  fullname: Friend, Peter J
– sequence: 8
  givenname: Marlene L
  surname: Rose
  fullname: Rose, Marlene L
– sequence: 9
  givenname: Susan V
  surname: Fuggle
  fullname: Fuggle, Susan V
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24978037$$D View this record in MEDLINE/PubMed
BookMark eNpNT9tKxDAUDLLiXvQXpL750pp7mkdZvMGCIutzSdITqLTJ2rSCf2_QFTwvc-bMMJxZo0WIARC6IrgiWKsbTKr9S4XzcM4o5ZWUWuKKqRO0IoLxUuIaL_7tS7RO6T37BVPqDC0p16rGTK2Qfo09FNEXJkxd-dkNkDH8MBvbDlKR2QjB9MU0mpAOfZbM1MVwjk696RNcHHGD3u7v9tvHcvf88LS93ZWOSUpKr1trqTVKUOk9Zdg4W_vaWKo8OABr8rlujWRcc6581rhSWBjtBAbn6AZd_-YexvgxQ5qaoUsO-vwIxDk1RHBKc30hsvXyaJ3tAG1zGLvBjF_NX136Db4_W2M
CitedBy_id crossref_primary_10_1016_j_lfs_2019_116666
crossref_primary_10_1016_j_humimm_2019_06_010
crossref_primary_10_1111_tan_14858
crossref_primary_10_1159_000511322
crossref_primary_10_1111_ajt_13866
crossref_primary_10_3389_fimmu_2021_703457
crossref_primary_10_1097_MOT_0000000000000335
crossref_primary_10_1097_TP_0000000000003551
crossref_primary_10_1371_journal_pone_0231646
crossref_primary_10_1016_j_humimm_2019_04_009
crossref_primary_10_3390_antib13020044
crossref_primary_10_1111_tan_13581
crossref_primary_10_1016_j_trre_2016_06_001
crossref_primary_10_1111_1756_185X_14990
crossref_primary_10_1016_j_trim_2017_09_001
crossref_primary_10_3389_fimmu_2017_00322
crossref_primary_10_1111_iji_12494
crossref_primary_10_1016_j_cellimm_2020_104131
crossref_primary_10_1016_j_transproceed_2016_04_009
crossref_primary_10_3389_fcvm_2022_919036
crossref_primary_10_1111_iji_12641
crossref_primary_10_12688_f1000research_10445_1
crossref_primary_10_1002_art_38885
crossref_primary_10_1097_MOT_0000000000000688
crossref_primary_10_1053_j_ajkd_2015_03_033
crossref_primary_10_1155_2017_8746303
crossref_primary_10_1016_j_humimm_2019_03_017
crossref_primary_10_4103_ijot_ijot_57_20
crossref_primary_10_1111_ctr_12567
crossref_primary_10_1038_modpathol_2017_123
crossref_primary_10_3389_fimmu_2017_00434
crossref_primary_10_3390_jcm9041193
crossref_primary_10_1111_ajt_15493
crossref_primary_10_1053_j_ajkd_2019_06_010
crossref_primary_10_3390_transplantology1010003
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1097/01.TP.0000443224.66960.37
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1534-6080
ExternalDocumentID 24978037
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-~X
.-D
.XZ
.Z2
01R
0R~
123
1J1
40H
4Q1
4Q2
4Q3
53G
5RE
5VS
77Y
7O~
AAAAV
AAAXR
AAGIX
AAHPQ
AAIQE
AAJCS
AAMOA
AAMTA
AARTV
AASOK
AAUEB
AAXQO
AAYEP
ABBUW
ABDIG
ABJNI
ABOCM
ABPPZ
ABXVJ
ABZAD
ACCJW
ACDDN
ACDOF
ACEWG
ACGFO
ACGFS
ACIJW
ACILI
ACWDW
ACWRI
ACXNZ
ACZKN
ADGGA
ADHPY
AE3
AE6
AEETU
AENEX
AFDTB
AFEXH
AFNMH
AFUWQ
AGINI
AHOMT
AHQNM
AHVBC
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJZMW
ALKUP
ALMA_UNASSIGNED_HOLDINGS
AMJPA
AMNEI
BOYCO
BQLVK
C45
CGR
CS3
CUY
CVF
DIWNM
DU5
DUNZO
E.X
EBS
ECM
EIF
EJD
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FL-
H0~
HZ~
IH2
IKREB
IKYAY
IN~
J5H
JK3
JK8
K8S
KD2
KMI
L-C
L7B
N9A
NPM
N~7
N~B
O9-
OAG
OAH
ODMTH
OHYEH
OL1
OLG
OLH
OLU
OLV
OLY
OLZ
OPUJH
OVD
OVDNE
OVIDH
OVLEI
OVOZU
OWV
OWW
OWY
OWZ
OXXIT
P2P
RLZ
S4R
S4S
TEORI
V2I
VVN
W3M
WOQ
WOW
X3V
X3W
XYM
YFH
YOC
ZFV
ZZMQN
7X8
ABPXF
ADKSD
ID FETCH-LOGICAL-c3621-f9dbb2ba7526ff230acb8f8ab27feceeba6ff8da6349447f8f847705a9c50ecc2
IEDL.DBID 7X8
ISICitedReferencesCount 36
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=00007890-201407150-00011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1534-6080
IngestDate Mon Sep 08 03:56:27 EDT 2025
Thu Apr 03 07:05:53 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3621-f9dbb2ba7526ff230acb8f8ab27feceeba6ff8da6349447f8f847705a9c50ecc2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 24978037
PQID 1542296055
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1542296055
pubmed_primary_24978037
PublicationCentury 2000
PublicationDate 2014-Jul-15
20140715
PublicationDateYYYYMMDD 2014-07-15
PublicationDate_xml – month: 07
  year: 2014
  text: 2014-Jul-15
  day: 15
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Transplantation
PublicationTitleAlternate Transplantation
PublicationYear 2014
SSID ssj0005377
Score 2.3134322
Snippet The role of non-HLA antibodies in rejection is not clear. We investigate whether antibodies to vimentin are made after renal transplantation and if production...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 72
SubjectTerms Adult
Atrophy
Biopsy
Female
Fibrosis
HLA Antigens - immunology
Humans
Immunoglobulin G - blood
Immunoglobulin M - blood
Isoantibodies - blood
Kidney Diseases - blood
Kidney Diseases - immunology
Kidney Diseases - pathology
Kidney Transplantation - adverse effects
Male
Middle Aged
Retrospective Studies
Risk Factors
Time Factors
Treatment Outcome
Vimentin - immunology
Title Role of anti-vimentin antibodies in renal transplantation
URI https://www.ncbi.nlm.nih.gov/pubmed/24978037
https://www.proquest.com/docview/1542296055
Volume 98
WOSCitedRecordID wos00007890-201407150-00011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEB7USvHio_VRX2xBvKW22ewme5IiFg-2FKnSW0k2CRTqbm1rwX_vJN3akyB4Wcg-QphMMt9MZr8BuMGZlIZqRUQiLGEiNSQJLfo8UiVNwTVPfS2Ct2fe64nhMOkXAbd5kVa53hP9Rq3z1MXI79DUU4pwO4rupx_EVY1yp6tFCY1tKIUIZZxW8-GGLTwKfeVFXNSMxAiNylD_IW1sNQZ9T17IGOo0a8Qxdt4I-e9I01uczsF_x3oI-wXWDNor5TiCLZNVoNrO0M9-_wpuA5_96cPqFSh3i0P2KiQv-cQEuQ1Q6GOy9PT_48y3VO6SDgNszYzreuGp0Sdy9f9SdgyvncfBwxMpKiyQFA1Xi9hEK0WV5BGNrUVvRKZKWCEV5dag-VQSbwstY0diw7jFZ4zzZiSTNGri5NMT2MnyzJxBEDLHRahTzph7kwpNLTU21oJKw4yuQX0tqxFqsDuWkJnJP-ejjbRqcLoS-Gi6otoYUVcArxny8z98fQF7iGaYC7y2oksoWVy_5gp20-ViPJ9de9XAa6_f_QZIEcJa
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Role+of+anti-vimentin+antibodies+in+renal+transplantation&rft.jtitle=Transplantation&rft.au=Besarani%2C+Dler&rft.au=Cerundolo%2C+Lucia&rft.au=Smith%2C+John+D&rft.au=Procter%2C+Jeanette&rft.date=2014-07-15&rft.issn=1534-6080&rft.eissn=1534-6080&rft.volume=98&rft.issue=1&rft.spage=72&rft_id=info:doi/10.1097%2F01.TP.0000443224.66960.37&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1534-6080&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1534-6080&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1534-6080&client=summon